10-Q: Atossa Therapeutics Q3 Loss Widens Amid R&D Surge

Atossa Therapeutics reported a wider net loss in Q3 2025, driven by increased research and development expenses for its lead breast cancer drug candidate, (Z)-endoxifen, while engaging with the FDA on accelerated regulatory pathways.

Summary

• Net loss for the three months ended September 30, 2025, was $8.7 million, compared to $7.2 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $23.8 million, compared to $19.2 million for the same period in 2024.
• Cash and cash equivalents decreased to $51.8 million as of September 30, 2025, from $71.1 million at December 31, 2024.
• Research and development (R&D) expenses increased by 57% to $5.37 million for Q3 2025 and by 40% to $15.03 million for the nine months ended September 30, 2025, compared to the prior year periods.
• General and administrative (G&A) expenses increased by 31% to $3.88 million for Q3 2025 and by 9% to $10.68 million for the nine months ended September 30, 2025, compared to the prior year periods.
• The company used $19.2 million in cash for operating activities during the nine months ended September 30, 2025.
• Management believes current cash and cash equivalents are sufficient to fund operations for at least one year from the filing date (November 12, 2025).
• Preliminary data from the Karisma-(Z)-endoxifen Phase 2 study showed significant mammographic breast density (MBD) reduction: 17.3% for the 1 mg dose and 23.5% for the 2 mg dose, with the 1 mg dose showing a favorable safety profile.
• The company received positive written feedback from the FDA regarding its proposed global Phase 2 dose optimization trial for (Z)-endoxifen in ER+/HER2metastatic breast cancer.
• Updated results from the I-SPY 2 EOP study showed 65% of patients achieved a Ki-67<10% response at Week 3, and median functional tumor volume decreased 77.7% from baseline to surgery, with (Z)-endoxifen being well tolerated.
• The Phase 2 EVANGELINE study for neoadjuvant ER+/HER2breast cancer was amended to a single-arm, open-label design with 40-65 patients, focusing on objective, short-interval endpoints.
• The company received an extension until February 17, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price rule, but has not yet regained compliance after a subsequent monitoring period.
• Intas Pharmaceuticals Ltd. filed petitions with the USPTO PTAB on April 3, 2025, seeking to invalidate two of the company's patents related to (Z)-endoxifen, which the PTAB granted institution for on November 3, 2025.

Sentiment

Score: 5

Explanation: The filing presents a mixed picture. Positive clinical updates and active FDA engagement for accelerated pathways are balanced by widening net losses, significant cash burn, ongoing Nasdaq compliance issues, and new patent challenges. The company's financial position shows increased liabilities and decreased cash, indicating continued reliance on future capital raises. The positive clinical data is often preliminary or from amended trials, adding a layer of uncertainty.

Positives

• Preliminary data from the Karisma-(Z)-endoxifen Phase 2 study demonstrated significant mammographic breast density (MBD) reduction, with the 1 mg dose reducing MBD by 17.3% (p<0.01) and the 2 mg dose by 23.5% (p<0.01), and the 1 mg dose showing a favorable safety profile.
• Received positive written feedback from the FDA regarding the proposed global Phase 2 dose optimization trial for (Z)-endoxifen in ER+/HER2metastatic breast cancer, affirming key elements of the clinical development plan.
• Updated results from the I-SPY 2 EOP study showed strong antitumor activity, with 65% of patients achieving a Ki-67<10% response at Week 3 and median functional tumor volume decreasing 77.7% from baseline to surgery, with (Z)-endoxifen being well tolerated.
• Management believes current cash and cash equivalents of $51.8 million will be sufficient to finance operations for at least one year from the date the financial statements were issued (November 12, 2025).
• Patent protection for proprietary (Z)-endoxifen is secured through at least November 17, 2038.

Negatives

• Net loss widened to $8.7 million for the three months ended September 30, 2025, from $7.2 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $23.8 million from $19.2 million in the prior year period.
• Cash and cash equivalents decreased by $19.2 million during the nine months ended September 30, 2025, from $71.1 million to $51.8 million.
• Operating cash flow was negative $19.2 million for the nine months ended September 30, 2025.
• Interest income decreased by $0.4 million for Q3 2025 and $1.3 million for the nine months, primarily due to lower average cash balances.
• The company has not yet regained compliance with Nasdaq's $1.00 minimum bid price rule, despite an extension until February 17, 2026, and a period where the stock traded above $1.00 for 10 consecutive days, as Nasdaq required an additional 10 days.
• An impairment charge of $1.7 million was recorded in Q3 2024 for an investment in Dynamic Cell Therapies, Inc. (DCT), which subsequently ceased operations.
• The 2 mg dose of (Z)-endoxifen in the Karisma study was associated with higher rates of hot flashes, night sweats, and vaginal discharge compared to placebo.
• A liability of $1.5 million was recorded for potential disqualification of Australian R&D tax rebates based on an ATO taxpayer alert.
• Warrants totaling 17,837,500 expired in 2025, with no warrants remaining outstanding at September 30, 2025.

Risks

• The company has a history of operating losses and expects to continue incurring losses in the future.
• No established sources of ongoing revenue exist to cover operating costs and ensure the company's continuation as a going concern.
• Substantial additional capital will be needed in the future, and there is no assurance such funds will be available on acceptable terms.
• Any products developed may never achieve significant commercial market acceptance.
• The company may be unable to establish sales, marketing, and commercial supply capabilities.
• The loss of the services of the Chief Executive Officer could adversely affect the business.
• Acquisitions, collaborations, licenses, and investments may not yield expected benefits, as demonstrated by the $1.7 million impairment charge on the DCT investment.
• Difficulty in locating, attracting, and retaining experienced and qualified personnel could adversely affect the business.
• Compounds appearing promising in research and development may fail to reach later stages, or clinical trials may take longer than expected or fail entirely.
• Interim, top-line, or preliminary clinical trial data reports may ultimately differ from actual results once data are more fully evaluated.
• Failure to obtain or maintain the regulatory approvals required to develop or commercialize products.
• Patient deaths in clinical trials, even if unrelated to the drugs, could negatively impact the business.
• Dependence on third-party service providers for critical operational activities, manufacturing, testing, and clinical trials poses risks of failure or delay.
• Products and services may expose the company to possible litigation and product liability claims.
• The deployment of artificial intelligence (AI) in product candidates could adversely affect the business, reputation, or financial results due to flaws, bias, or public acceptance issues.
• Business disruptions, including natural disasters, severe weather, and pandemics, could seriously harm future revenue and financial condition.
• Cash held at financial institutions often exceeds federally-insured limits, posing a risk in case of bank failure.
• The ability to use net operating loss carryforwards and research tax credits to reduce future tax payments may be limited or restricted by tax laws.
• The company or its Australian subsidiary could lose the ability to operate in Australia or benefit from R&D tax rebates.
• Inaccurate estimates or assumptions in preparing financial statements could lead to actual results varying from accruals.
• Inability to protect proprietary technology could lead to direct competition.
• Compliance with various procedural, document submission, and fee payment requirements is crucial for maintaining patent protection.
• Changes in U.S. patent law could diminish the value of patents in general.
• Inability to protect intellectual property rights throughout the world.
• The current patent portfolio may not include all patent rights needed, and future licenses may not be available on commercially reasonable terms.
• Third-party claims alleging intellectual property infringement may prevent or delay drug discovery and development efforts.
• Risk of employees, consultants, or independent contractors wrongfully using or disclosing confidential information of third parties.
• Inability to adequately prevent disclosure of trade secrets and other proprietary information.
• Legislative or regulatory reforms may make it more difficult and costly to obtain regulatory approval and to manufacture, market, and distribute products.
• Disruptions at the FDA and other government agencies could negatively affect the review of regulatory submissions.
• Inadvertent or unintentional failure to comply with complex government regulations concerning patient privacy (e.g., HIPAA, GDPR) could subject the company to fines and adversely affect its reputation.
• Significant disruptions in information technology systems or breaches of data security could adversely affect the business.
• Failure to comply with complex federal and state laws and regulations related to submission of claims for services could result in significant monetary damages and penalties.
• Significant competition from other biotechnology and pharmaceutical companies, including those utilizing AI technologies.
• Risk of employees and third-party partners engaging in misconduct or other improper activities.
• Business involves risks associated with handling hazardous and other dangerous materials.
• Inability to regain or maintain compliance with Nasdaq's continued listing standards could lead to delisting.
• The sale of a substantial number of common stock shares into the market may cause substantial dilution and stock price decline.
• The trading price of common stock has been and is likely to continue to be volatile.
• The company has never paid dividends and does not anticipate paying dividends in the future.
• Ownership of common stock may become concentrated among a small number of stockholders.
• Inability to implement and maintain effective internal control over financial reporting could negatively affect investor confidence.
• Requirements of being a public company may strain resources, result in litigation, and divert management's attention.
• Anti-takeover provisions in governing documents and Delaware law could delay or prevent a change in control.
• The exclusive forum provision in the Certificate of Incorporation could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Inaccurate or unfavorable research by securities or industry analysts could cause the stock price and trading volume to decline.

Future Outlook

The company expects to meet with the FDA on November 17, 2025, to discuss a development plan for (Z)-endoxifen, including potential expedited programs for a New Drug Application (NDA) filing, with FDA meeting minutes expected in December 2025. A successful alignment with the FDA could potentially shorten development timelines and reduce future clinical costs. The company is targeting an IND submission for a global Phase 2 dose optimization trial for (Z)-endoxifen in ER+/HER2metastatic breast cancer for the fourth quarter of 2025. Top-line data for the Karisma-(Z)-endoxifen study is expected in the first quarter of 2026. The company anticipates incurring ongoing operating losses for the foreseeable future as it continues to develop its therapeutic programs and will need to raise substantial additional capital to fund its business plan over the next several years.

Management Comments

• "Management believes its currently available cash and cash equivalents will be sufficient to finance the Company's operations for at least one year from the date these Condensed Consolidated Financial Statements are issued."
• "The Company plans to continue to fund its losses from operations and capital funding needs through a combination of public or private equity offerings, debt financings or other sources, including potential corporate collaborations, licenses and other similar arrangements."
• "While there can be no assurance of a favorable outcome, a successful alignment with the FDA could potentially materially shorten development timelines and reduce future clinical costs."
• "We believe that this approach [pursuing metastatic breast cancer indication] may offer a more streamlined regulatory pathway to deliver (Z)-endoxifen to patients with urgent unmet medical needs as the current treatment options for metastatic breast cancer often provides limited durability of response and substantial side effects."
• "We expect to incur ongoing operating losses for the foreseeable future as we continue to develop our planned therapeutic programs, including related clinical studies and other programs in the pipeline."

Industry Context

The company operates in the highly competitive clinical-stage biopharmaceutical sector, specifically focusing on oncology with a lead candidate, (Z)-endoxifen, for breast cancer. Its strategic pursuit of an accelerated regulatory pathway for metastatic breast cancer aligns with industry efforts to address urgent unmet medical needs in severe conditions. The company's engagement in collaborative trials like I-SPY 2 EOP reflects a common industry approach to leverage broader research networks. The mention of AI deployment in product candidates indicates an awareness and potential adoption of emerging technologies in drug discovery, a growing trend in the biopharma industry, though it also acknowledges the associated risks. The company faces significant competition from larger, more established pharmaceutical and biotechnology firms with greater resources and experience.

Comparison to Industry Standards

• The company's participation in the I-SPY 2 Endocrine Optimization Pilot (I-SPY 2 EOP) is a collaboration with academic investigators, Quantum Leap Healthcare Collaborative, the FDA, and the Foundation for the National Institutes of Health (FNIH) Cancer Biomarkers Consortium, which is a recognized platform for evaluating new breast cancer therapies.
• The use of Ki-67 response and functional tumor volume measurement as primary and secondary endpoints in clinical trials (e.g., EVANGELINE, I-SPY 2 EOP) are standard and widely accepted metrics in oncology drug development for assessing tumor proliferation and response.
• The company's focus on ER+/HER2breast cancer addresses a significant patient population, as this subtype accounts for approximately 78% of all new breast cancer cases each year, aligning with major disease burdens in the industry.
• The filing notes that reduction in mammographic breast density (MBD) alone may not be an approvable indication unless a reduction in breast cancer incidence is also demonstrated, which is consistent with the FDA's rigorous requirements for clinical benefit in preventative indications.

Corporate Governance

Legal Proceedings

• On April 3, 2025, Intas Pharmaceuticals Ltd. filed a Petition for Post Grant Review (PGR) with the U.S. Patent and Trademark Office's (USPTO) Patent Trial and Appeal Board (PTAB) seeking to invalidate U.S. Patent No. 12,071,391, titled 'Methods for Making and Using Endoxifen,' on alleged grounds of anticipation, obviousness, lack of written description, and lack of enablement.
• On April 3, 2025, Intas also filed a Petition for Inter Partes Review (IPR) with the USPTO's PTAB seeking to invalidate U.S. Patent No. 11,261,151, titled 'Methods for Making and Using Endoxifen,' on alleged grounds of anticipation and obviousness.
• On November 3, 2025, the PTAB released a Decision Granting Institution of PGR for U.S. Patent No. 12,071,391 and a Decision Granting Institution of IPR for U.S. Patent No. 11,261,151.
• The company intends to vigorously contest these petitions and believes the patents were properly granted and include valid and enforceable claims, with the risk of experiencing financial loss related to the petitions being remote.
• The company has a deadline of January 26, 2026, to respond to the 391 PGR Petition and the 151 IPR Petition.
• Previously, on January 29, 2025, the PTAB issued a final written decision finding all claims of U.S. Patent No. 11,572,334, titled 'Methods for Making and Using Endoxifen,' unpatentable in a separate proceeding initiated by Intas Pharmaceuticals Ltd.

Stakeholder Impact

• **Shareholders**: Face potential dilution from future capital raises, stock price volatility due to ongoing Nasdaq compliance issues and patent challenges, and the long-term value proposition is tied to successful drug development and commercialization.
• **Employees**: Benefit from stock-based compensation and defined contribution plan matching contributions, but face uncertainty regarding the company's long-term financial stability and ability to attract and retain talent in a competitive market.
• **Future Patients**: Stand to benefit from the potential development of new breast cancer treatments, including for prevention, metastatic, and neoadjuvant settings, but face risks of clinical trial delays or failures.
• **Creditors**: Exposed to increased liabilities and the company's reliance on future capital raises to fund its operations and meet contractual obligations.
• **Suppliers/Contract Research Organizations (CROs)**: Continue to be critical partners for manufacturing and clinical trials, with existing contractual obligations, but face risks related to the company's funding and potential changes in development plans.

Next Steps

• Meet with the FDA on November 17, 2025, to discuss a development plan for (Z)-endoxifen, including potential expedited programs.
• Evaluate implications for plans and timelines following receipt of FDA meeting minutes, expected in December 2025.
• Target IND submission for a global Phase 2 dose optimization trial for (Z)-endoxifen in ER+/HER2metastatic breast cancer for Q4 2025.
• Respond to the 391 PGR Petition and the 151 IPR Petition by January 26, 2026.
• Release top-line data for the Karisma-(Z)-endoxifen study in Q1 2026.
• Continue enrollment in the RECAST study for Ductal Carcinoma in Situ (DCIS).
• Continue enrollment in the amended EVANGELINE study for neoadjuvant ER+/HER2breast cancer.
• Continue efforts to regain Nasdaq compliance by the extended deadline of February 17, 2026.
• Assess the potential impact of recently issued accounting pronouncements (ASU No. 2024-03 and ASU No. 2023-09).

Key Dates

Recommendation

The company is a clinical-stage biopharmaceutical entity with no current revenue, operating in a high-risk, high-reward sector. While there are promising preliminary clinical data for (Z)-endoxifen in multiple indications and active engagement with the FDA for accelerated regulatory pathways, the financial performance shows widening net losses and significant cash burn. The ongoing Nasdaq compliance issue and patent invalidation proceedings introduce substantial uncertainty. A 'Hold' recommendation is appropriate, reflecting the potential for future upside from successful drug development balanced against significant financial and operational risks. Investors should closely monitor FDA interactions, clinical trial progress, and capital raising efforts.

Keywords

Atossa Therapeutics, (Z)-endoxifen, Breast Cancer, Oncology, Clinical Trials, Biopharmaceutical, Mammographic Breast Density, Metastatic Breast Cancer, Ductal Carcinoma in Situ, Neoadjuvant Therapy, FDA, SEC Filing, 10-Q, Drug Development, SERM, Patent Litigation, Nasdaq Compliance, Financial Results, I-SPY 2 EOP, EVANGELINE study, Karisma study